Antisense oligonucleotides tarageting folate receptor alpha,...

Organic compounds -- part of the class 532-570 series – Organic compounds – Carbohydrates or derivatives

Reexamination Certificate

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Details

C536S024100, C536S023100, C514S04400A, C435S320100

Reexamination Certificate

active

07030236

ABSTRACT:
The invention relates to treatment of cancers and cancerous cells which over-express α folate receptor (FRα) compared to the normal cells of the same tissue. The invention is directed to antisense oligonucleotides which are complimentary to the coding region of FRα, as well as the pharmaceutical compositions made thereof, and the methods of using the same for treatment of cancers, e.g. cancers of ovary, cervix, uterus, and brain.

REFERENCES:
patent: 5998148 (1999-12-01), Bennett et al.
patent: 6096880 (2000-08-01), Kool
patent: 6180353 (2001-01-01), Dean et al.
Hansen et al., Teratology vol. 59(6):385, Jun. 1999.
Jhaveri et al., Proceedings of the American Association for Cancer Research Annual Meeting, No. 41, p. 643, Mar. 2000.
Xin-Lau et al The Journal of Biological Chemistry, vol. 271(41):25539-25547, 1996.

LandOfFree

Say what you really think

Search LandOfFree.com for the USA inventors and patents. Rate them and share your experience with other people.

Rating

Antisense oligonucleotides tarageting folate receptor alpha,... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Antisense oligonucleotides tarageting folate receptor alpha,..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Antisense oligonucleotides tarageting folate receptor alpha,... will most certainly appreciate the feedback.

Rate now

     

Profile ID: LFUS-PAI-O-3525780

  Search
All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.